Lana Kandalaft, PharmD, MTR, PhD, from the University of Pennsylvania School of Medicine, describes a study that examined a novel two-step immunotherapy for women with advanced ovarian cancer.
Lana Kandalaft, PharmD, PhD
Advertisement
Articles by Lana Kandalaft, PharmD, PhD
Advertisement
Latest Updated Articles
Dr. Kandalaft on an Ovarian Cancer ImmunotherapyMarch 5th 2013
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5